This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Warfield, K. L.
Right arrow Articles by Bavari, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Warfield, K. L.
Right arrow Articles by Bavari, S.
Right arrowPubmed/NCBI databases
*Protein

 Previous Article  |  Next Article 

Journal of Virology, July 2009, p. 6404-6415, Vol. 83, No. 13
0022-538X/09/$08.00+0     doi:10.1128/JVI.00126-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Development and Characterization of a Mouse Model for Marburg Hemorrhagic Fever{triangledown}

Kelly L. Warfield,* Steven B. Bradfute, Jay Wells, Loreen Lofts, Meagan T. Cooper, D. Anthony Alves, Daniel K. Reed, Sean A. VanTongeren, Christine A. Mech, and Sina Bavari*

United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702

Received 19 January 2009/ Accepted 1 April 2009

The lack of a mouse model has hampered an understanding of the pathogenesis and immunity of Marburg hemorrhagic fever (MHF), the disease caused by marburgvirus (MARV), and has created a bottleneck in the development of antiviral therapeutics. Primary isolates of the filoviruses, i.e., ebolavirus (EBOV) and MARV, are not lethal to immunocompetent adult mice. Previously, pathological, virologic, and immunologic evaluation of a mouse-adapted EBOV, developed by sequential passages in suckling mice, identified many similarities between this model and EBOV infections in nonhuman primates. We recently demonstrated that serially passaging virus recovered from the liver homogenates of MARV-infected immunodeficient (SCID) mice was highly successful in reducing the time to death in these mice from 50 to 70 days to 7 to 10 days after challenge with the isolate MARV-Ci67, -Musoke, or -Ravn. In this study, we extended our findings to show that further sequential passages of MARV-Ravn in immunocompetent mice caused the MARV to kill BALB/c mice. Serial sampling studies to characterize the pathology of mouse-adapted MARV-Ravn revealed that this model is similar to the guinea pig and nonhuman primate MHF models. Infection of BALB/c mice with mouse-adapted MARV-Ravn caused uncontrolled viremia and high viral titers in the liver, spleen, lymph node, and other organs; profound lymphopenia; destruction of lymphocytes within the spleen and lymph nodes; and marked liver damage and thrombocytopenia. Sequencing the mouse-adapted MARV-Ravn strain revealed differences in 16 predicted amino acids from the progenitor virus, although the exact changes required for adaptation are unclear at this time. This mouse-adapted MARV strain can now be used to develop and evaluate novel vaccines and therapeutics and may also help to provide a better understanding of the virulence factors associated with MARV.

* Corresponding author. Present address for Kelly L. Warfield: Integrated BioTherapeutics Inc., 20358 Seneca Meadows Parkway, Germantown, MD 20876. Phone: (240) 454-8936. Fax: (240) 515-0324. E-mail: kelly{at}integratedbiotherapeutics.com. Mailing address for Sina Bavari: USAMRIID, 1425 Porter Street, Fort Detrick, MD 21702. Phone: (301) 619-4246. Fax: (301) 619-2290. E-mail: sina.bavari{at}us.army.mil

{triangledown} Published ahead of print on 15 April 2009.

Journal of Virology, July 2009, p. 6404-6415, Vol. 83, No. 13
0022-538X/09/$08.00+0     doi:10.1128/JVI.00126-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»